đ Pathogenesis of Diabetes:
Diabetes āĻāĻāĻāĻž multifactorial diseaseāĨ¤ āĻ āϰā§āĻĨāĻžā§ āĻ āύā§āĻ āϰāĻāĻŽā§āϰ factor āĻāϰ interplay āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻāĻ disease āĻšā§ā§ āĻĨāĻžāĻā§āĨ¤ āĻāĻ factor āĻā§āϞ⧠āĻŽā§āϞāϤ ⧍āĻāĻž category āϤ⧠āĻĒā§ā§ – genetic factors āĻāϰ environmental factorsāĨ¤
â Pathogenesis of Type-1 diabetes:
āĻĒā§āϰāĻĨāĻŽā§āĻ āĻāϏāĻŋ type 1 diabetes āĻāϰ pathogenesis āĻāĨ¤ āĻāĻāĻŋ āĻŽā§āϞāϤ āĻāĻāĻāĻž autoimmune disease, āĻ āϰā§āĻĨāĻžā§ āĻāĻāĻžāύ⧠body āĻāϰ āύāĻŋāĻā§āϰ immune system āύāĻŋāĻā§āϰ cells & tissues (āĻāĻā§āώā§āϤā§āϰ⧠pancreas āĻāϰ β cell) āĻā§ attack āĻāϰā§āĨ¤ Ultimate effect āĻšāĻā§āĻā§ Î˛ cell āĻāϰ destructionāĨ¤
Type 1 diabetes āĻāϰ āĻā§āώā§āϤā§āϰ⧠genetic factor āĻā§āϞā§āĻ āĻĒā§āϰāϧāĻžāύ āĻā§āĻŽāĻŋāĻāĻž āϰāĻžāĻā§āĨ¤ āĻĒā§āϰāĻžā§ ā§Šā§ĻāĻāĻŋāϰ āĻŦā§āĻļāĻŋ gene āĻāϰ mutation āĻāϰ āϏāĻžāĻĨā§ type 1 diabetes āĻāϰ āϏāĻŽā§āĻĒāϰā§āĻ āĻĒāĻžāĻā§āĻž āĻāĻŋā§ā§āĻā§āĨ¤ āĻāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠MHC āĻŦāĻž HLA gene cluster āĻāϰ mutation āϏāĻŦāĻā§ā§ā§ common, āĻĒā§āϰāĻžā§ ā§Ģā§Ļ%āĨ¤ Non-MHC gene āĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§ insulin gene, CTLA4 gene, PTPN22 gene, Autoimmune Regulator (AIRE) gene āĻāϤā§āϝāĻžāĻĻāĻŋāĨ¤

āĻŽā§āϞāϤ genetic factor āĻā§āϞā§āĻ āĻĻāĻžā§ā§ āĻšāϞā§āĻ āĻāĻŋāĻā§ environmental factor āĻāϰ āĻā§āĻŽāĻŋāĻāĻžāĻ āϰā§ā§āĻā§ type 1 diabetes āĻāϰ pathogenesis āĻāĨ¤ āϧāĻžāϰāĻŖāĻž āĻāϰāĻž āĻšā§ āϝā§, āĻāĻŋāĻā§ viral infection āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ autoimmune process āĻāĻž trigger āĻšāϤ⧠āĻĒāĻžāϰ⧠āϝāĻžāϰ āĻŽā§āϞ āĻāĻžāϰāĻŖ āĻšāĻŋāϏā§āĻŦā§ āϧāϰāĻž āĻšā§ā§āĻā§ molecular mimicryāĨ¤ āĻ āϰā§āĻĨāĻžā§, viral antigen āĻā§āϞā§āϰ āϏāĻžāĻĨā§ host antigen āĻāϰ structure āĻ āĻŽāĻŋāϞ āĻĨāĻžāĻāĻžā§ cross-react āĻāϰā§āĨ¤
Type 1 diabetes āĻāϰ āĻŽā§āϞ abnormality āĻ āĻšāĻā§āĻā§ failure of self-toleranceāĨ¤ āĻāĻ failure āĻ āύā§āĻāĻāĻžāĻŦā§āĻ āĻšāϤ⧠āĻĒāĻžāϰ⧠– āϝā§āĻŽāύ self-reactive T cell āĻāϰ clonal deletion āϝāĻĻāĻŋ defective āĻšā§ āĻ āĻĨāĻŦāĻž regulatory T cell āĻāϰ function āϝāĻĻāĻŋ defective āĻšā§āĨ¤ Ultimately, āĻāĻ self-reactive T cell āĻā§āϞā§āĻ Î˛ cell āĻāϰ destruction āĻāϰā§āĨ¤ Helper T cell āĻā§āϞ⧠āύāĻžāύāĻžāϰāĻāĻŽ cytokine āϝā§āĻŽāύ TNF, IFN-Îŗ āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ damage āĻāϰā§, āĻ āύā§āϝāĻĻāĻŋāĻā§ cytotoxic T cell āĻā§āϞ⧠directly damage āĻāϰā§āĨ¤
āĻāĻāĻžā§āĻžāĻ islet autoantigen āĻāϰ against āĻ autoantibody āĻ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ āĻāĻŋāύā§āϤ⧠autoantibody āĻā§āϞ⧠cell damage āĻāϰ⧠āĻāĻŋāύāĻž āĻŦāĻž āĻāϰāϞā§āĻ āĻāĻŋāĻāĻžāĻŦā§ āĻāϰ⧠āϤāĻž āĻāĻāύ⧠āϏāĻ āĻŋāĻāĻāĻžāĻŦā§ āĻāĻžāύāĻž āϝāĻžā§āύāĻŋ, āϤāĻžāĻ autoantibody āĻā§āϞ⧠predictive marker āĻšāĻŋāϏā§āĻŦā§ use āĻāϰāĻž āĻšā§āĨ¤
āĻāĻāϝ⧠islet autoantigen āĻāϰ āĻāĻĨāĻž āĻŦāϞāϞāĻžāĻŽ āϝāĻžāĻā§ target āĻāϰ⧠T cell āĻā§āϞ⧠activate āĻšā§ āĻāĻŦāĻžāϰ antibody āĻ āϤā§āϰāĻŋ āĻšāĻā§āĻā§, āĻāĻ islet autoantigen āĻāϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§
- insulin (insulin āĻĒā§āϰā§āĻāĻŋāύ āĻāϰ against āĻāĻ autoimmunity āĻšāĻā§āĻā§),
- β cell GAD (GAD āĻšāϞ⧠āĻāĻāĻāĻž āĻāύāĻāĻžāĻāĻŽ, glutamic acid decarboxylase) āĻāĻŦāĻ
- islet cell autoantigen 512
āϤāĻžāĻšāϞ⧠āĻĒā§āϰ⧠process āĻāĻž āĻĻāĻžāĻā§āĻžāĻā§āĻā§ āĻ āύā§āĻāĻāĻž āĻāϰāĻāĻŽ –
genetic & environmental factors ⤠failure of self-tolerance ⤠activation of self-reactive T cells against islet antigens ⤠damage of β cells ⤠insulin deficiency ⤠Type 1 DM
Type 2 Diabetes, āĻāĻāĻžāύā§āĻ genetic factor āĻāϰ environmental factor āϝāĻĻāĻŋāĻ āĻāĻāĻžāύ⧠environmental factor āĻā§āϞā§āϰ āĻĒā§āϰāĻāĻžāĻŦ āĻŦā§āĻļāĻŋāĨ¤ āĻāϰ āĻāĻāĻž Type 1 āĻāϰ āĻŽāϤ āĻā§āύ⧠autoimmune disease āύāĻžāĨ¤
Genetic factor āϝā§āĻā§āϞ⧠āϰā§ā§āĻā§ āϏā§āĻā§āϞ⧠āϏāĻŦāĻ insulin secretion āĻāϰ āϏāĻžāĻĨā§ related geneāĨ¤ āĻ āϰā§āĻĨāĻžā§ āĻāĻāĻžāύ⧠genetic defect āĻā§āϞāĻžāϰ āĻāĻžāϰāĻŖā§ insulin āĻāϰ secretion āĻ abnormality āĻšāĻŦā§āĨ¤
Environmental factor āĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻšāĻā§āĻā§ obesityāĨ¤ āĻāϰ āĻĒāϰā§āĻ āϰā§ā§āĻā§ sedentary life styleāĨ¤
â Pathogenesis of type-2 diabetes:
āĻāĻŦāĻžāϰ āĻāϏāĻŋ āĻāĻŋāĻāĻžāĻŦā§ āĻāϏāϞ⧠type 2 diabetes āĻāĻž āĻšāĻā§āĻā§āĨ¤ āĻāĻāĻžāύ⧠āĻŽā§āϞāϤ ⧍ āϰāĻāĻŽ defect āĻĻā§āĻāĻž āϝāĻžā§ – insulin resistance āĻāĻŦāĻ Î˛ cell dysfunctionāĨ¤

āĻĒā§āϰāĻĨāĻŽāĻĻāĻŋāĻā§ insulin resistance āĻĻāĻŋā§ā§ āĻļā§āϰ⧠āĻšā§, āϤāĻāύ āĻāĻā§ compensate āĻāϰāϤ⧠āĻāĻŋā§ā§ β cell āĻāϰ function āĻŦā§ā§ā§ āϝāĻžā§ āĻāĻŦāĻ hyperinsulinemia āĻĻā§āĻāĻž āϝāĻžā§āĨ¤ āĻāĻŋāύā§āϤ⧠āϏāĻŽā§ā§āϰ āϏāĻžāĻĨā§ āϏāĻžāĻĨā§ āĻāĻ āϏāĻŽā§ Î˛ cell āĻā§āϞ⧠āĻāϰ adapt āĻāϰāϤ⧠āĻĒāĻžāϰā§āύāĻž āĻāϰ āϤāĻāύ āĻĨā§āĻā§āĻ āĻļā§āϰ⧠āĻšā§ Î˛ cell dysfunctionāĨ¤
âž Insulin Resistance:
āϝāĻāύ insulin āĻāϰ target tissue āĻā§āϞ⧠āĻ āϰā§āĻĨāĻžā§ liver, skeletal muscle, adipose tissue āĻāϰ āϏāĻ āĻŋāĻāĻāĻžāĻŦā§ insulin āĻāϰ āĻĒā§āϰāϤāĻŋ respond āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āύāĻž, āϤāĻāύ āϤāĻžāĻā§ insulin resistance āĻŦāϞā§āĨ¤
Insulin resistance āĻāϰ āĻ āύā§āϝāϤāĻŽ āĻĒā§āϰāϧāĻžāύ āĻāĻžāϰāĻŖ āĻšāĻā§āĻā§ obesity.
â Obesity āĻāĻŋāύā§āϤ⧠distribution āĻ āύā§āϏāĻžāϰ⧠⧍ āϰāĻāĻŽ, central āĻāϰ peripheralāĨ¤ āĻāϰ āĻŽāϧā§āϝ⧠central fat āĻā§āϞā§āϤ⧠lipolysis āĻŦā§āĻļāĻŋ āĻšā§āĨ¤ āĻĢāϞ⧠āĻŦā§āĻļāĻŋ āĻŦā§āĻļāĻŋ fatty acid āϤā§āϰāĻŋ āĻšā§ that is excess free fatty acids (FFAs) in bloodāĨ¤ āĻāĻ excess FFAs āĻāĻŋā§ā§ cell āĻāϰ āĻāĻŋāϤāϰā§āϰ oxidation pathway āĻā§āϞā§āĻā§ overwhelm āĻāϰ⧠āĻĢā§āϞā§āĨ¤ āĻĢāϞ⧠āĻĻā§āĻāĻž āϝāĻžā§ pathway āĻā§āϞ⧠āĻ āĻŋāĻāĻŽāϤ⧠āĻāϞāϤ⧠āĻĒāĻžāϰ⧠āύāĻž āĻāĻŦāĻ āĻāϏāĻŦ pathway āĻāϰ āĻāĻŋāĻā§ intermediate product āĻā§āώ āĻāϰ āĻāĻŋāϤāϰ⧠āĻāĻŽāϤ⧠āĻĨāĻžāĻā§āĨ¤ āĻāϰāĻāĻŽ āĻāĻāĻāĻŋ intermediate product āĻšāĻā§āĻā§ diacylglycerol (DAG)āĨ¤ āĻāĻ DAG āĻāĻŋā§ā§ insulin āĻāϰ intracellular āϝ⧠signalling āĻšā§ āϏā§āĻāĻžāϰ āϏāĻžāĻĨā§ interfere āĻāϰā§āĨ¤ Ultimately, insulin āĻāϰ desired effect āĻāĻž āĻĒāĻžāĻā§āĻž āϝāĻžā§ āύāĻž, result is insulin resistanc.
â āĻāĻ excess FFA āĻā§āϞ⧠āĻāĻŦāĻžāϰ cell āĻāϰ āĻāĻŋāϤāϰ⧠oxidation āĻāϰ āĻāύā§āϝ glucose āĻāϰ āϏāĻžāĻĨā§ compete āĻāϰā§āĨ¤ āϝāϤ āĻŦā§āĻļāĻŋ āĻŦā§āĻļāĻŋ fatty acid āĻāϰ oxidation āĻšā§, glucose āĻāϰ oxidation āϤāϤ āĻāĻŽāϤ⧠āĻĨāĻžāĻā§, this leads to accumulation of glucoseāĨ¤ Cell āĻāϰ āĻāĻŋāϤāϰ⧠glucose āĻāĻŽā§ āĻā§āϞ⧠āĻŦāĻžāĻāϰ⧠āĻĨā§āĻā§ āĻ āϰā§āĻĨāĻžā§ blood āĻĨā§āĻā§ glucose entry āĻāĻŽā§ āϝāĻžāĻŦā§, āϤāĻāύ blood āĻ glucose level āĻŦāĻžā§āϤ⧠āĻĨāĻžāĻāĻŦā§, that is hyperglycemiaāĨ¤
â āĻāĻāĻžā§āĻžāĻ obesity āϤ⧠adiponectin level āĻāĻŽā§ āϝāĻžāĻā§āĻžāϰ āĻāĻžāϰāĻŖā§āĻ blood glucose level āĻŦāĻžā§ā§āĨ¤ āĻāĻ adiponectin āĻšāϞ⧠āĻāĻ āϧāϰāĻŖā§āϰ adipokine (adipose tissue āĻĨā§āĻā§ release āĻšāĻā§āĻž āĻāĻŋāĻā§ āĻĒā§āϰā§āĻāĻŋāύ āĻā§ adipokine āĻŦāϞā§)āĨ¤ Adipokine āĻŽā§āϞāϤ blood glucose āĻāĻŽāĻžā§, obesity āϤ⧠adipokine level āĻāĻŽā§ āϝāĻžā§ āĻŦāϞ⧠blood glucose level āĻŦā§ā§ā§ āϝāĻžā§āĨ¤

➠β cell dysfunction:
āĻ
āύā§āĻāĻĻāĻŋāύ āϧāϰ⧠insulin resistance āĻāϞāϤ⧠āĻĨāĻžāĻāϞ⧠āĻāĻ āϏāĻŽā§ Î˛ cell āĻā§āϞ⧠āĻāϰ adapt āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āύāĻž āĻāĻŦāĻ āĻļā§āϰ⧠āĻšā§ Î˛ cell dysfunctionāĨ¤ excess FFAs āĻāĻŦāĻ chronic hyperglycemia āĻāϰ āĻāĻžāϰāĻŖā§āĻ āĻŽā§āϞāϤ β cell dysfunction āĻšāϤ⧠āĻĨāĻžāĻā§āĨ¤
đ Sign-symptoms of Diabetes:
āϏāĻŦāĻā§āϝāĻŧā§ āϏāĻžāϧāĻžāϰāĻŖ āĻāĻĒāϏāϰā§āĻāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§:
âĻ āĻā§āĻŦ āϤā§āώā§āĻŖāĻž āĻĒāĻžāĻāϝāĻŧāĻž
âĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻā§āϰ āĻāĻžāĻāϤā§āĻ āĻāύ āĻāύ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāĻāϝāĻŧāĻžāĨ¤ āĻŦāĻŋāĻļā§āώ āĻāϰ⧠āϰāĻžāϤā§āϰ āĻŦā§āϞāĻžāϝāĻŧāĨ¤
âĻ āĻā§āϞāĻžāύā§āϤ āĻŦā§āϧ āĻāϰāĻž
âĻ āĻā§āύ āĻāĻžāϰāĻŖ āĻāĻžāĻĄāĻŧāĻžāĻ āĻāĻāύ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻž
âĻ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻā§ āĻŦāĻžāϰāĻŦāĻžāϰ āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻāϝāĻŧāĻž
âĻ āĻĻā§āώā§āĻāĻŋ āĻāĻžāĻĒāϏāĻž āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž
âĻ āĻļāϰā§āϰā§āϰ āĻā§āĻĨāĻžāĻ āĻā§āĻā§ āĻā§āϞ⧠āϏā§āĻāĻž āĻļā§āĻāĻžāϤ⧠āĻĻā§āϰāĻŋ āĻšāĻā§āĻž
āĻāĻŋāĻāĻŋā§āϏāĻāϰāĻž āĻŦāϞāĻā§āύ, type-1 diabetes sign-symptoms āĻļā§āĻļāĻŦ āĻĨā§āĻā§āĻ āĻĻā§āĻāĻž āĻĻāĻŋāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ āĻŦāϝāĻŧāϏ āĻŦāĻžāĻĄāĻŧāĻžāϰ āϏāĻžāĻĨā§ āϏā§āĻāĻž āĻāϰ⧠āĻāĻāĻŋāϞ āĻšāϝāĻŧā§ āĻāĻ āϤ⧠āĻĒāĻžāϰā§āĨ¤

āĻŦāϝāĻŧāϏ ā§Ēā§Ļ āĻŦāĻāϰā§āϰ āĻŦā§āĻļāĻŋ āĻšāĻāϝāĻŧāĻžāϰ āĻĒāϰ āĻĨā§āĻā§ type-2 diabetes āĻāϰ āĻā§āĻāĻāĻŋ āĻŦā§āĻĄāĻŧā§ āϝāĻžāϝāĻŧāĨ¤ āϤāĻŦā§ āĻĻāĻā§āώāĻŋāĻŖ āĻāĻļāĻŋāϝāĻŧāĻžāϰ āϞā§āĻāĻāύā§āϰ āĻŽāϧā§āϝ⧠āĻāĻ āĻā§āĻāĻāĻŋ āϤā§āϰāĻŋ āĻšāϝāĻŧ āϤāĻžāĻĻā§āϰ ⧍ā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ āĻšāĻāϝāĻŧāĻžāϰ āĻĒāϰ āĻĨā§āĻā§āĻāĨ¤
āϝāĻžāĻĻā§āϰ āĻĒāĻŋāϤāĻžāĻŽāĻžāϤāĻž, āĻāĻžāĻ āĻŦā§āύā§āϰ diabetes āĻāĻā§, āĻ āĻĨāĻŦāĻž āϝāĻžāĻĻā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻāύ, āĻĻāĻā§āώāĻŋāĻŖ āĻāĻļāĻŋāϝāĻŧāĻžāϰ āĻā§āύ āĻĻā§āĻļā§āϰ āĻŽāĻžāύā§āώ, āĻāĻĢā§āϰā§-āĻā§āϝāĻžāϰāĻŋāĻŦāĻŋāϝāĻŧāĻžāύ āĻ āĻĨāĻŦāĻž āĻā§āώā§āĻŖāĻžāĻā§āĻ āĻāĻĢā§āϰāĻŋāĻāĻžāύ āϤāĻžāĻĻā§āϰāĻ āĻāĻ āĻā§āĻāĻāĻŋ āĻŦā§āĻļāĻŋ āĻĨāĻžāĻā§āĨ¤
đ Complications of Diabetes:

Diabetes āĻāϰ complications āĻā§āϞā§āĻā§ āĻŽā§āϞāϤ ā§Š āĻāĻžāĻā§ āĻāĻžāĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
â Macro vascular complications ( āϝā§āĻāĻžāύ⧠āĻŦā§ āϰāĻā§āϤāύāĻžāϞ⧠āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšā§):
âĻ Coronary artery disease (CAD)
e.g: ischaemic heart attack
âĻ Cerebro vascular disease (CVD)
e.g: stroke, transient ischaemic attack
âĻ Peripheral vascular disease (PVD)
e.g: feet gangrene
â Micro vascular complications ( āϝā§āĻāĻžāύ⧠āĻā§āĻ āϰāĻā§āϤāύāĻžāϞ⧠āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšā§)
âĻ Diabetic neuropathy
âĻ Diabetic nephropathy
âĻ Diabegic retinopathy
â Diabetic cataract
āĻāĻāĻžā§āĻž āĻāĻ āĻŽāĻšāĻžāĻŽāĻžāϰ⧠āĻāϰ āϏāĻŽā§ā§ āϏāĻŦāĻā§ā§ā§ āĻŦā§āĻļāĻŋ āĻā§āĻāĻŋāϤ⧠diabetic patientāĨ¤āĻāĻŽāĻžāĻĻā§āϰ āĻĻā§āĻļā§ diabetes āϰā§āĻā§āϰ āϏāĻāĻā§āϝāĻž āĻ āύā§āĻāĨ¤ āĻŦāĻŋāĻļā§āώ āĻāϰ⧠āĻŦā§āϏā§āĻ āĻŦā§āϝāĻā§āϤāĻŋāĻĻā§āϰ āĻ āύā§āĻā§āϰāĻ diabetes āĻāĻā§āĨ¤ āϤāĻžāϰ āĻāĻĒāϰ āĻāĻŽāĻžāĻĻā§āϰ diabetes āϰā§āĻā§āĻĻā§āϰ āĻāĻāĻāĻŋ āĻŦāĻŋāϰāĻžāĻ āĻ āĻāĻļā§āϰ blood glucose āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻŦāĻžāĻāϰā§āĨ¤ diabetes āĻāϰ āĻāĻžāϰāĻŖā§ āϰā§āĻā§āĻĻā§āϰ āϰā§āĻ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžā§āĨ¤ āĻāĻāĻžā§āĻžāĻ pandemic situation āĻāϰ āĻāύā§āϝ āĻ āύā§āĻā§ patient exercise āĻāϰāϤ⧠āĻĒāĻžāϰāĻā§āύāĻž āϝā§āĻāĻžāϰ āĻāĻžāϰāĻŖā§ uncontrolled diabetes āĻšāĻā§āĻā§āĨ¤ āϝā§āĻā§āύ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āϏāĻā§āĻā§ āϞā§āĻžāĻ āĻāϰāĻžāϰ āϏāĻā§āώāĻŽāϤāĻž āĻšā§āϰāĻžāϏ āĻĒāĻžā§āĨ¤ āĻāĻŦāĻžāϰ diabetes āϰā§āĻā§āĻĻā§āϰ āĻāĻāĻ āϏāĻā§āĻā§ kidney disease, heart disease āĻāϤā§āϝāĻžāĻĻāĻŋ āĻĨāĻžāĻā§āĨ¤ diabetes āϰā§āĻā§āĻĻā§āϰ āĻŦā§ āϧāϰāύā§āϰ āĻā§āĻāĻāĻŋ āĻāĻā§ corona virus āĻ āϏāĻāĻā§āϰāĻŽāĻŋāϤ āĻšāĻā§āĻžāϰ āĻā§āώā§āϤā§āϰā§āĨ¤
Reference:
âĻ Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, United States: Saunders; 2015. Chapter 24: The Endocrine System; p1109-1112.
âĻ Pearson ER, McCrimmon RJ. Diabetes Mellitus. In: Ralston SH, Penman ID, Strachan MWJ, & Hobson R. (Eds.). Davidsonâs Principles and Practice of Medicine. 23rd ed. London, England: Elsevier Health Sciences; 2018. p725-727.
Platform Academic Divison/
āĻāϏāĻžāĻĻā§āϞ āĻāϞ āĻāĻžāϞāĻŋāĻŦ
āϏā§āϝāĻžāϰ āϏāϞāĻŋāĻŽā§āϞā§āϞāĻžāĻš āĻŽā§āĻĄāĻŋāĻā§āϞ āĻāϞā§āĻ
āϏā§āĻļāύāĻ⧍ā§Ļā§§ā§Ŧ-⧍ā§Ļā§§ā§
āύā§āĻšāĻž āĻāĻžāύ
āĻāĻāύāĻŋāĻāĻžāϰā§āϏā§āϞ āĻŽā§āĻĄāĻŋāĻā§āϞ āĻāϞā§āĻ
āϏā§āĻļāύāĻ⧍ā§Ļā§§ā§-⧍ā§Ļā§§ā§Ž
Pingback: The father of the deaf and his battle with Diabetes || Part-04 – Platform | CME